Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant

Transplantation

Volumn 97, Issue 9, 2014, Pages 946-952

  Aubert, Olivier ^a   Suberbielle, Caroline ^b   Gauthe, Remi ^c   Francois, Helene ^a,d   Obada, Erika Nnang ^a   Durrbach, Antoine ^a,d  

^a BICÊTRE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Anti HLA antibodies; Bortezomib; Desensitization; Immunized patients; Renal transplantation

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; HLA ANTIBODY; ANTIBODY; BORONIC ACID DERIVATIVE; HLA ANTIGEN; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; STEROID;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DESENSITIZATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFECTION; KIDNEY GRAFT; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIZATION; THROMBOCYTOPENIA; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; NEUTROPHIL; PREOPERATIVE PERIOD; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES; BORONIC ACIDS; DEXAMETHASONE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEUTROPHILS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; PROTEASOME INHIBITORS; PYRAZINES; RENAL INSUFFICIENCY; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903775683     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438207.42465.40     Document Type: Article

References (29)

1. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Tansplant 2007; 7: 408.
2. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Tansplant 2007; 7: 864.
3. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
4. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
5. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol 2009; 162: 13.
6. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchYpositive recipients. Transplantation 2000; 70: 887.
7. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
8. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402.
9. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitiza-tion with IVIG and rATG. Am J Transplant 2008; 8: 133.
10. Medina F, Segundo C, Campos-Caro A, et al. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002; 99: 2154.
11. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748.
12. Patel J, Everly M, Chang D, et al. Reduction of alloantibodies via pro-teasome inhibition in cardiac transplantation. J Heart Lung Transplant 2011; 30: 1320.
13. Shapiro R. Reducing antibody levels in patients undergoing transplantation. N Engl J Med 2008; 359: 305.
14. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
15. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous im-munoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
16. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747.
17. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004; 17: 1.
18. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
19. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
20. Diwan TS, Raghavaiah S, Burns JM, et al. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011; 91: 536.
21. Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitorYbased therapy. Transplantation 2012; 93: 572.
22. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
23. Guthoff M, Schmid-Horch B, Weisel KC, et al. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012; 26: 171.
24. Wahrmann M, Haidinger M, Kormoczi GF, et al. Effect of the pro-teasome inhibitor bortezomib on humoral immunity in two pre-sensitized renal transplant candidates. Transplantation 2010; 89: 1385.
25. Bisping G, Wenning D, Kropff M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3Yspecific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009; 15: 520.
26. Schmidt N, Alloway RR, Walsh RC, et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 2012; 94: 352.
27. Stewart AK. Novel therapeutics in multiple myeloma. Hematology 2012; 17: S105.
28. Fu W, Delasalle K, Wang J, et al. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol 2012; 35: 562.
29. Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010; 84: 223.